Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice-Reference-Cited by-同舟云学术

Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice

Published:2017-04-06 Issue:35 Volume:8 Page:58353-58363
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Obara Koki¹,Shirakami Yohei¹²,Maruta Akinori¹,Ideta Takayasu¹,Miyazaki Tsuneyuki¹,Kochi Takahiro¹,Sakai Hiroyasu¹,Tanaka Takuji³,Seishima Mitsuru²,Shimizu Masahito¹

Affiliation:

1. Department of Gastroenterology, Gifu University Graduate School of Medicine, Gifu, Japan

2. Department of Informative Clinical Medicine, Gifu University Graduate School of Medicine, Gifu, Japan

3. Department of Pathological Diagnosis, Gifu Municipal Hospital, Gifu, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential;Frontiers in Pharmacology;2024-03-26

2. Inhibition of Sodium-Glucose Cotransporter-2 during Serum Deprivation Increases Hepatic Gluconeogenesis via the AMPK/AKT/FOXO Signaling Pathway;Endocrinology and Metabolism;2024-02-29

3. Deciphering the Causal Relationship between Sodium-glucose Cotransporter 2 Inhibition and Cancer Risks: A Comprehensive Mendelian Randomization Study;Journal of Cancer;2024

4. Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis;Metabolism;2023-08

5. Anti-Glycolytic Drugs in the Treatment of Hepatocellular Carcinoma: Systemic and Locoregional Options;Current Oncology;2023-07-10